Recent Research in Substance Use Disorders and Other Mental Health Problems

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Mental Health".

Deadline for manuscript submissions: closed (20 December 2021) | Viewed by 3408

Special Issue Editors


E-Mail Website
Guest Editor
Center for Alcohol and Drug Research, University of Aarhus, 8000 Aarhus, Denmark
Interests: co-occurring substance use disorder and mental health; personality disorder; prospective studies; attention-deficit/hyperactivity disorder; cannabis; psychometrics; psychoeducation

E-Mail Website
Guest Editor
Center for Alcohol and Drug Research, University of Aarhus, 8000 Aarhus, Denmark
Interests: co-occurring substance use disorder and mental health; antisocial personality disorder; overdoses; suicide; opioids; treatment; marginalization

Special Issue Information

Dear Colleagues,

For several decades it has been known that a high proportion of people with substance use disorders struggle with other mental health issues, including common disorders such as anxiety and depression, and less common disorders such as personality disorders, such as ADHD and autism. However, while much progress has been made in identifying and addressing the complex problems related to this co-morbidity, there is still room for improvement.

We are interested in papers on recent research related to the many aspects of substance use disorders and other mental health problems.

Paper topics may include (but are not limited to) epidemiology, assessment issues, prognostic significance, mechanisms of change between disorders, pharmacologic and behavioral treatment, new treatment models and interventions, gender and ethnic issues, special populations (e.g. opiod antagonist treatment, criminal justice populations, health care professionals), cross-sectorial collaboration, policy, legal issues, harm reduction, and recovery.

Prof. Morten Hesse
Prof. Birgitte Thylstrup
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Substance use disorders
  • Mental health
  • Co-moribidty
  • Integrated treatment
  • Parallel treatment
  • Dual-focus treatment
  • Co-occurring disorders
  • Cocaine
  • Alcohol
  • Cannabis
  • Opioids
  • Amphetamines

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

9 pages, 234 KiB  
Article
Levels of Impulsivity, Hyperactivity, and Inattention and the Association with Mental Health and Substance Use Severity in Opioid-Dependent Patients Seeking Treatment with Extended-Release Naltrexone
by Ann Tarja Karlsson, John-Kåre Vederhus, Thomas Clausen, Bente Weimand, Kristin Klemmetsby Solli and Lars Tanum
J. Clin. Med. 2021, 10(19), 4558; https://doi.org/10.3390/jcm10194558 - 30 Sep 2021
Cited by 8 | Viewed by 2761
Abstract
The level of impulsivity, hyperactivity, and inattention (IHI) is higher among patients with substance use disorder (SUD) than in the general population. However, the prevalence of such symptoms in patients seeking treatment with an opioid antagonist, such as extended-release naltrexone (XR-NTX), is unknown. [...] Read more.
The level of impulsivity, hyperactivity, and inattention (IHI) is higher among patients with substance use disorder (SUD) than in the general population. However, the prevalence of such symptoms in patients seeking treatment with an opioid antagonist, such as extended-release naltrexone (XR-NTX), is unknown. We screened 162 patients with opioid use disorder (OUD) seeking treatment with XR-NTX in Norway using the Adult ADHD Self-Report Scale (ASRS) to estimate the prevalence of IHI alongside an assessment of mental and physical health and substance use. Sixty-six patients scored above the clinical cut-off on the ASRS. Higher levels of IHI were significantly associated with a longer history of frequent amphetamine use, current alcohol use, and greater mental distress. Mental distress was the strongest factor associated with higher levels of IHI. The introduction of screening for IHI and mental distress in opioid maintenance treatment and XR-NTX would likely improve the quality of care and enable clinicians to tailor interventions to the needs of patients with high levels of IHI to prevent treatment discontinuation. Full article
Back to TopTop